Post-Authorization Long-Term Safety Study of LUTATHERA

International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours

Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).

To assess the incidence and nature of potential long-term safety outcomes in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. Retrospective and prospective data will be used.

Inclusion Criteria:

• adult patients (fulfilling the definition of "age of majority" per local regulations),
• with unresectable or metastatic, well-differentiated, somatostatin receptor positive GEP-NETs
• and who were treated with Lutathera (regardless of the quantity and number of doses administered and whatever the reasons for ending).

Exclusion Criteria:

• Hypersensitivity to Lutathera (active substance or any of the excipients),
• presence of established or suspected pregnancy or pregnancy not excluded,
• presence of kidney failure with creatinine clearance < 30 mL/min.